ESMO 2023 BioNTech Data

10 1. Partnered with Duality Bio.. • Anti-tumor activity in heavily pretreated patients with 3 median prior lines of treatment All patients (n=23) NSCLC (n=13) BNT325/DB-13051 Demonstrated Antitumor Activity in Patients With NSCLC and Other Solid Tumors Phase 1/2a FIH study (NCT05438329): Clinical Efficacy Marathe O. et al. Presented at ESMO 2023. Poster #689P. Antitumor activity was also observed in a patient with fallopian tube cancer: 1 unconfirmed PR at 5 mg/kg: ORR, 1/1 Unconfirmed ORR, % 30.4 Unconfirmed DCR, % 87.0 46.2 92.3 Best Change from Baseline (%) FIH = first in human; ORR = objective response rate; DCR disease control rate; NSCLC = non-small cell lung cancer; CRC = colorectal cancer; TNBC = triple-negative breast cancer; GC = gastric cancer; GEJC = gastroesophageal junction cancer. -50 50 00 CRC NSCLC NSCLC CRC Best tumor response for all patients with post-baseline scans (n=23): NSCLC TNBC APPENDICEAL DUODENAL Subject name or identifer Dose level 2 mg/kg 4 mg/kg 5 mg/kg 6 mg/kg NSCLC CRC CRC GC/GEJC NSCLC BIONTECH NSCLC NSCLC NSCLC NSCLC NSCLC NSCLC NSCLC Ampullary Fallopian tube NSCLC

View entire presentation